Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines
Conditions
Interventions
botulinum toxin
Placebo
Locations
14
United States
\Ablon Skin Institute and Research Center
Manhattan Beach, California, United States
Moradi MD
Vista, California, United States
Etre Cosmetic Dermatology and Laser Center
New Orleans, Louisiana, United States
Maryland Dermatology, Laser Skin & Vein
Hunt Valley, Maryland, United States
Skin Specialist, PC
Omaha, Nebraska, United States
Robert Schwarcz, MD, PC
New York, New York, United States
Start Date
February 10, 2020
Primary Completion Date
August 7, 2020
Completion Date
January 5, 2021
Last Updated
June 18, 2023
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT05217355
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions